Ticker

Findings support the ongoing Phase 1 clinical development of BBI-940, an oral, selective kinesin degrader, as a potential first-in-class therapy for select advanced or metastatic breast cancers Findings support the ongoing Phase 1 clinical development of BBI-940, an oral, selective kinesin degrader, as a potential first-in-class therapy for select advanced or metastatic breast cancers

Boundless Bio offers a highly asymmetric risk/reward profile, trading at a $25M valuation with $107.6M in cash and a runway into 2H 2028. BBI-940, BOLD's first direct ecDNA-targeting asset, is entering clinical trials with promising preclinical efficacy, high selectivity, and a rational mechanism of action. Previous clinical failures (BBI-825, BBI-335) targeted indirect vulnerabilities, but BBI-940 directly…

Press Release            Lesquin, 20 February 2026, 7.30 NACON announces the temporary suspension of trading in its shares on Euronext Paris Lesquin, 20 February 2026, Nacon (the “Company”) announces that it has requested Euronext Paris to temporarily suspend trading in its shares on the Euronext Paris regulated (ISIN : FR0013482791) as of market opening today. On 17 February 2026, the Company acknowledges the press…